Gadolinium (Gd) is a silvery-white, malleable and ductile rare-earth metal.
Because of the extremely high neutron cross-section of Gadolinium, this element is very effective for use with:
The chemical medium helps to provide clear and detailed pictures of internal organs that can then be used to “more accurately report on how your body is working and whether there is any disease or abnormality present.”
Gadolinium contrast dyes were approved for use in MRI scans in 1988.
It is now the most commonly used chemical medium for MRIs.
Gadolinium contrast agents, used to enhance MRI films, can be extremely dangerous.
Over the past several years it has become apparent that Gadolinium contrast dyes can cause two separate diseases:
Gadolinium Deposition Disease occurs in individuals with normal or near-normal renal function “who develop persistent symptoms that arise within a few hours to two months after the administration of Gadolinium-based contrast agents (GBCAs).”
In order to diagnose individuals with the disease, a urine test must be administered that confirms the presence of Gadolinium in the body.
This test should be administered 30 or more days after the most recent GBCA was used.
Until recently, a diagnosis for patients with normal to near-normal renal function did not exist, making the disease a relatively new concept.
It is unclear how many individuals actually suffer from Gadolinium Deposition Disease.
The following are five (5) well-known Gadolinium Contrast Dyes on the market:
NSF is a rare diagnosis.
There have been no reports of NSF in patients with normal kidney function or with those with mild-to-moderate kidney insufficiency.
However, if you suspect you may have kidney issues, you should be screened prior to receiving one of these imaging agents.
Furthermore, the recommended dose should not be exceeded and enough time should elapse to ensure that a dose has been eliminated from the body before the agent is used again.
In May 2006, the Danish Medicines Agency was one of the first groups to report NSF traces.
The agency reported 25 cases of NSF occurring in Denmark and Austria alone.
In May 2007, Dr. Melanie Blank, an FDA kidney specialist, issued a report concluding that:
An “undeniable and strong association” existed between contrast agents containing Gadolinium and NSF.
Originally thought to be a skin disorder, the diagnosis was termed Nephrogenic Fibrosing Dermopathy (NFD).
Gradually, the diagnosis produced wider symptoms and it is now considered a systemic disorder referred to as Nephrogenic Systemic Fibrosis (NSF).
Some of the initial signs of NSF/NSD are:
Symptoms are similar to NSF, but vary in a few notable ways:
TorHoerman Law is no longer accepting Gadolinium Nephrogenic Systemic Fibrosis (NSF) cases.
NSF is a disease also caused by Gadolinium, with the first diagnosis occurring in 1997.
Currently, the Center for Disease Control has information about 315 patients with NSF.
Sadly, at the present time, there are more questions than there are answers about the disease.
There are very few effective treatments for NSF, and there is no cure.
“Drug Safety and Availability – FDA Drug Safety Communication: FDA Evaluating the Risk of Brain Deposits with Repeated Use of Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (MRI).” U.S. Food and Drug Administration Home Page, U.S. Department of Health and Human Services,www.fda.gov/Drugs/DrugSafety/ucm455386.htm
“Drug Safety and Availability – FDA Drug Safety Communication: FDA Warns That Gadolinium-Based Contrast Agents (GBCAs) Are Retained in the Body; Requires New Class Warnings.” U.S. Food and Drug Administration Home Page, U.S. Department of Health and Human Services,www.fda.gov/Drugs/DrugSafety/ucm589213.htm
Ferris, Nick, and Stacy Goergen. “Gadolinium Contrast Medium (MRI Contrast Agents).”InsideRadiology, 26 July 2017,www.insideradiology.com.au/gadolinium-contrast-medium/
Fornell, Dave. “The Debate Over Gadolinium MRI Contrast Toxicity.” Imaging Technology News, 16 Feb. 2018,www.itnonline.com/article/debate-over-gadolinium-mri-contrast-toxicity
“Gadolinium-Based Contrast Agents (GBCAs) and Nephrogenic Systemic Fibrosis (NSF).” DIVISION OF MEDICAL IMAGING AND HEMATOLOGY PRODUCTS MEMORANDUM TO THE FILE,s3.amazonaws.com/propublica/assets/omniscan/blank-melanie-review-omniscan2.pdf
“Gadolinium Deposition Disease – Part of a Family of Disorders.” Gadolinium Toxicity, 30 May 2016,gadoliniumtoxicity.com/2016/05/30/gadolinium-deposition-disease-family-of-disorders/
Goergen, Stacy. “Contrast Medium: Using Gadolinium or Iodine in Patients with Kidney Problems.” InsideRadiology, 26 July 2017,www.insideradiology.com.au/contrast-medium/
TorHoerman Law was responsible for handling a medical case for our family. I was extremely impressed with their professionalism and ability to react quickly. They also did a nice job keeping us updated with the case throughout the process. This was the first time experiencing a situation like this and Tor Hoerman law did an excellent job from start to finish.
TorHoerman Law is an extraordinary law firm – a firm that truly makes the client’s best interests the primary concern. Their team of personal injury lawyers are experienced, personable, and well versed in a range of litigation areas. They are supported by a dedicated team of staff that are as equally friendly and helpful. I would recommend TorHoerman Law for any personal injury litigation needs.
All of my questions were answered quickly and in a way I could understand. Steve and the entire staff were friendly and professional.
I highly recommend this law firm! The attorneys and staff at THL worked hard, communicated every step of the process, kept me well informed at all times, and exceeded all expectations! The staff is kind, considerate, professional, and very experienced. Look no further, call now!
Top-notch, hardworking attorneys!
A wonderful and professional legal team. They helped me when I needed expert legal representation! Thank you TorHoerman Law!
They contacted me the next day. Very nice people!